Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875176 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661478 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL851826 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL101673 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL660625 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| EP-3406614-B1 | OPIOID RECEPTOR ANTAGONIST CONJUGATE AND USE THEREOF | SHANGHAI HANMAI BIO PHARMA CO LTD (CN) | 2022-12-28 | — | — | EP | disclosed |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | Shanghai Hanmai Bio-Pharma Co., Ltd. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-10596268-B2 | Conjugate of dezocine and polyethylene glycol | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2020-03-24 | — | — | US | disclosed |
| US-20190298845-A1 | CONJUGATE OF DEZOCINE AND POLYETHYLENE GLYCOL | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2019-10-03 | — | — | US | disclosed |
| US-8551220-B2 | Sulfur dioxide absorbent comprising ionic liquid | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-10-08 | — | — | US | disclosed |
| US-20120042778-A1 | SULFUR DIOXIDE ABSORBENT COMPRISING IONIC LIQUID | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596268-B2 | Conjugate of dezocine and polyethylene glycol | OPRM1, DAO, DDO | USP2 560/4885TSHR 3924/4885KDM4E 1342/4885 |
| US-20120042778-A1 | SULFUR DIOXIDE ABSORBENT COMPRISING IONIC LIQUID | TST, CBS, ARSA | USP2 1241/4885TSHR 1824/4885KDM4E 1504/4885 |
| US-20190298845-A1 | CONJUGATE OF DEZOCINE AND POLYETHYLENE GLYCOL | OPRM1, DAO, DDO | USP2 560/4885TSHR 3924/4885KDM4E 1342/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
| US-11311533-B2 | Opioid receptor antagonist conjugate and use thereof | OPRL1, OPRM1, OGFR | USP2 2647/4885TSHR 347/4885KDM4E 2838/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.